Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
Authors:
- Vappu RantalaihoVRVappu Rantalaiho
- Markku KorpelaMKMarkku Korpela
- Leena LaasonenLLLeena Laasonen
- Hannu KautiainenHKHannu Kautiainen
- Salme JärvenpääSJSalme Järvenpää
- Pekka HannonenPHPekka Hannonen
- Marjatta Leirisalo-RepoMLMarjatta Leirisalo-Repo
- Harri BlåfieldHBHarri Blåfield
- Kari PuolakkaKPKari Puolakka
- Anna KarjalainenAKAnna Karjalainen
- Timo MöttönenTMTimo Möttönen
- the FIN-RACo Trial GroupTGthe FIN-RACo Trial Group
Open Access
- 24 June 2010
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (3) , R122
Abstract
Introduction: Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD. Methods: A cohort of 199 patients with early active RA were initially randomized to receive treatment with a combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN-RACo), or treatment with a single DMARD (initially, sulfasalazine) with or without prednisolone (SINGLE). After 2 years, the drug-treatment strategy became unrestricted, but still targeted remission. The radiographs of hands and feet were analyzed by using the Larsen score at baseline, 2, 5, and 11 years, and the radiographs of large joints, at 11 years. Results: Sixty-five patients in the FIN-RACo and 65 in the SINGLE group had radiographs of hands and feet available at baseline and at 11 years. The mean change from baseline to 11 years in Larsen score was 17 (95% CI, 12 to 26) in the FIN-RACo group and 27 (95% CI, 22 to 33) in the SINGLE group (P = 0.037). In total, 87% (95% CI, 74 to 94) and 72% (95% CI, 58 to 84) of the patients in the FIN-RACo and the SINGLE treatment arms, respectively, had no erosive changes in large joints at 11 years. Conclusions: Targeting to remission with tight clinical controls results in low radiologic progression in most RA patients. Patients treated initially with a combination of DMARDs have less long-term radiologic damage than do those treated initially with DMARD monotherapy. Trial registration: Current Controlled Trials ISRCTN18445519.Keywords
This publication has 23 references indexed in Scilit:
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals of the Rheumatic Diseases, 2009
- Effects of glucocorticoids on radiological progression in rheumatoid arthritisCochrane Database of Systematic Reviews, 2007
- Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatmentAnnals of the Rheumatic Diseases, 2006
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease‐modifying antirheumatic drugs: Five‐year experience from the FIN‐RACo studyArthritis & Rheumatism, 2004
- Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritisAnnals of the Rheumatic Diseases, 2003
- The benefits of early treatment in rheumatoid arthritis: Confounding by indication, and the issue of timingArthritis & Rheumatism, 2003
- Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable differenceArthritis & Rheumatism, 2002
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002